Jean-Philippe Collet.

Jean-Philippe Collet, M cialis 5 mg .D., Ph.D., Thomas Cuisset, M.D., Ph.D.D., Guillaume Cayla, M.D., Ph.D., Simon Elhadad, M.D., Christophe Pouillot, M.D., Patrick Henry, M.D., Ph.D., Pascal Motreff, M.D., Ph.D.D., Ziad Boueri, M.D., Ph.D., Loic Belle, M.D., Eric Van Belle, M.D., Ph.D.D., Pierre Aubry, M.D.D., Pierre Sabouret, M.D., Stephen A. O’Connor, M.B., B.Ch.D., Mathieu Kerneis, M.D., Christophe Saint-Etienne, M.D.D., Farzin Beygui, M.D., Ph.D., Johanne Silvain, M.D., Ph.D., Eric Vicaut, M.D., Ph.D., and Gilles Montalescot, M.D., Ph.D. For the ARCTIC Investigators: Bedside Monitoring to regulate Antiplatelet Therapy for Coronary Stenting Aspirin and Clopidogrel play a central role in the treating sufferers undergoing percutaneous coronary intervention.1 Up to one third of patients have inadequate platelet inhibition, with an elevated risk of events.2-5 Platelet-function testing can determine the amount of platelet reactivity during treatment at the bedside and potentially identify patients in whom adjustment of antiplatelet therapy is warranted to minimize the risks of both ischemic and bleeding complications.6 Cohort studies and meta-analyses have largely shown the prognostic value of high platelet reactivity during antiplatelet therapy in individuals undergoing coronary stenting.7,8 Randomized scientific trials have also proven that stronger platelet inhibition can reduce ischemic events in sufferers presenting with an acute coronary syndrome that’s invasively managed, but this comes at the cost of more bleeding complications.9-12 Two recent studies selected sufferers with large platelet reactivity during treatment with clopidogrel to be able to display the superiority of stronger P2Y12 inhibition; one study was bad, and the various other was interrupted prematurely.13,14 It is unknown whether individualized antiplatelet therapy in all patients undergoing bedside tests before and after stenting can enhance the long-term clinical outcome.

Related StoriesStudy explores diabetes screening for patients with severe mental illnessStudy suggests dependence on specific treatment options for adolescents with starting point type 2 diabetesStudy finds high prevalence of dehydration in the elderly living in UK care homes In his presentation Dr. Ashton will describe the barriers to clinically effective therapies in diabetic retinopathy and the issue of getting drugs to the back of the eye, where most diabetic vision disease manifests itself. He is likely to discuss emerging medication delivery technology, including those under development at pSivida, which can help to get drugs directly to the area of the attention where they could be most effective in treating the underlying disease.